Benjamin Shepherd | Associate Director Of Research and Development, Therapeutics

Benjamin Shepherd, Associate Director Of Research and Development, Therapeutics, Organovo

Benjamin Shepherd, PhD, Associate Director, R&D, Therapeutics – Dr. Shepherd has more than 15 years of experience in Tissue Engineering and Regenerative Medicine research.  Dr. Shepherd’s research in vascular biology and microvascular tissue engineering has been focused on the ability to use creative approaches to generate microvascular networks to support the fabrication and surgical implantation of prevascularized neotissues.  In addition to these research interests, he has successfully led early-stage research programs in liver biology, oncology and directed differentiation of stem cells within 3D tissues.  Prior to joining Organovo in 2009, he was an Associate Research Scientist at the Yale School of Medicine, where he also conducted postdoctoral training.  In addition to his appointment at Yale, he was a staff perfusionist at the University of Connecticut Health Center.  Dr. Shepherd is board certified clinical perfusionist (C.C.P.), received his Ph.D. in Physiological Sciences from the University of Arizona and a B.S. in Zoology from the University of Washington.


Conference Day 1: Thursday 16th May 2019 @ 12:10

Technology and Strategy Roundtables

25 senior level tables hosted by thought leaders on key challenges and opportunities in next-generation therapeutic development. Participants are invited to join the group discussions on a topic of importance to them.· At each roundtable, the moderator will talk for 5 minutes to introduce the topic highlighting particular challenges specific to that area· The table will then move on to discussion for 25 minutes.· There will then be one rotation, giving participants the opportunity to have join two round tables in total(2 x 30-minute rotations and max 15 PAX)

Table 9. Tissue engineering for organ regeneration

Conference Day 2: Friday 17th May 2019 @ 12:25

Panel Discussion: Harnessing the body's regenerative capabilities – therapeutic development from the clinic to commercialization 

This panel will examine and discuss the ways regenerative medicine is being revived in the biotech industry and how some companies are using these new techniques and platforms to create better, faster, safer and potentially curative treatment options for a multitude of disease indicationsKey topic: Moving from autologous to fully allogeneic cell therapy
last published: 29/Jan/19 11:45 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152


Jessica Robinson 
t/ +44 (0)207 092 1150


Issa Mauthoor 
+44 (0)207 092 1257